Zevra Therapeutics, Inc. ZVRA Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsAndOtherReceivablesNetCurrent.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s accounts receivable?
- Zevra Therapeutics, Inc. (ZVRA) reported accounts receivable of $22.1M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s accounts receivable changed year-over-year?
- Zevra Therapeutics, Inc.'s accounts receivable increased by 75.1% year-over-year, from $12.62M to $22.1M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s accounts receivable?
- Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s accounts receivable has grown at a 55.2% compound annual growth rate (CAGR), from $2.58M to $23.26M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.